SCHEDULE 13G 0001702202 XXXXXXXX LIVE Common Stock, $0.001 par value per share 06/09/2025 0001427570 ReShape Lifesciences Inc. 76090R408 18 Technology Drive, Suite 110 Irvine CA 92618 Rule 13d-1(c) L1 Capital Global Opportunities Master Fund, Ltd. E9 235000.00 0.00 235000.00 0.00 235000.00 N 9.85 FI ReShape Lifesciences Inc. 18 Technology Drive, Suite 110, Irvine, CA 92618 L1 Capital Global Opportunities Master Fund, Ltd. 161A Shedden Road, 1 Artillery Court, PO Box 10085 Grand Cayman, Cayman Islands KY1-1001 Cayman Islands Y 235,000 The amounts in Row (5), (7) and (9) represent 235,000 Common Stock. The percentage set forth on Row (11) of the cover page for the reporting person is based on 2,385,960 Common Stock outstanding after the offering, based on the Issuer's Prospectus Supplement filed under Rule 424(b)(5) with the Securities and Exchange Commission on June 9, 2025. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer's securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes. 9.85% 235,000 0 235,000 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. L1 Capital Global Opportunities Master Fund, Ltd. /s/ David Feldman 06/13/2025